Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics.
Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation.
The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006.
AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -1.64 Decreased by -3.80% | -1.57 Decreased by -4.46% |
| Mar 11, 24 | -1.59 Decreased by -70.97% | -1.60 Increased by +0.63% |
| Nov 2, 23 | -1.41 Decreased by -19.49% | -1.79 Increased by +21.23% |
| Aug 7, 23 | -1.50 Decreased by -30.43% | -1.70 Increased by +11.76% |
| May 11, 23 | -1.58 Decreased by -20.61% | -1.05 Decreased by -50.48% |
| Mar 1, 23 | -0.93 Increased by +17.70% | -0.96 Increased by +3.12% |
| Nov 8, 22 | -1.18 Decreased by -391.67% | -0.72 Decreased by -63.89% |
| Aug 8, 22 | -1.15 Decreased by -5.65 K% | -1.02 Decreased by -12.75% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 3.32 M Increased by +156.61% | -37.31 M Increased by +0.17% | Decreased by -1.12 K% Increased by +61.10% |
| Jun 30, 23 | 3.46 M Increased by +184.54% | -39.84 M Decreased by -6.80% | Decreased by -1.15 K% Increased by +62.47% |
| Mar 31, 23 | 1.37 M Increased by +41.65% | -48.45 M Decreased by -18.85% | Decreased by -3.53 K% Increased by +16.09% |
| Dec 31, 22 | 6.81 M Increased by +573.39% | -26.41 M Increased by +18.82% | Decreased by -387.97% Increased by +87.95% |
| Sep 30, 22 | 1.29 M Decreased by -93.81% | -37.37 M Decreased by -460.62% | Decreased by -2.89 K% Decreased by -8.96 K% |
| Jun 30, 22 | 1.22 M Decreased by -95.95% | -37.31 M Decreased by -8.60 K% | Decreased by -3.07 K% Decreased by -214.65 K% |
| Mar 31, 22 | 970.00 K Decreased by -91.38% | -40.76 M Decreased by -124.42% | Decreased by -4.20 K% Decreased by -2.50 K% |
| Dec 31, 21 | 1.01 M Decreased by -98.31% | -32.54 M Decreased by -196.71% | Decreased by -3.22 K% Decreased by -5.84 K% |